SCHEMBL4333754

SCHEMBL4333754

CN(C)CCNC(=S)N/N=C/c1ccc(-c2ccc(Cl)c(Cl)c2)o1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.63
MAPT P10636 8/20 0.63
MEN1 O00255 7/20 0.63
ALDH1A1 P00352 7/20 0.63
HPGD P15428 6/20 0.63
HTT P42858 2/20 0.63
NPSR1 Q6W5P4 2/20 0.63
PHGDH O43175 5/20 0.60
LMNA P02545 3/20 0.53
TDP1 Q9NUW8 3/20 0.53
POLB P06746 3/20 0.53
KDM4E B2RXH2 5/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C19 P33261 1/20 0.52
ALOX12 P18054 1/20 0.52
MAPK1 P28482 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
BLM P54132 1/20 0.50
GAA P10253 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4333758 1.00 KMT2A (0.63) KMT2AMAPTMEN1ALDH1A1HPGD
SCHEMBL4341230 0.87 KMT2A (0.68) KMT2AMAPTMEN1ALDH1A1HPGD
SCHEMBL4341235 0.87 KMT2A (0.68) KMT2AMAPTMEN1ALDH1A1HPGD
SCHEMBL13886982 0.86 PHGDH (0.77) KMT2AMAPTMEN1ALDH1A1HPGD
SCHEMBL4455860 0.86 PHGDH (0.77) KMT2AMAPTMEN1ALDH1A1HPGD
SCHEMBL4331505 0.84 MEN1 (0.61) KMT2AMAPTMEN1ALDH1A1HPGD
SCHEMBL4331498 0.84 MEN1 (0.61) KMT2AMAPTMEN1ALDH1A1HPGD
SCHEMBL13887126 0.82 KMT2A (0.74) KMT2AMAPTMEN1ALDH1A1HPGD
SCHEMBL4453439 0.82 KMT2A (0.74) KMT2AMAPTMEN1ALDH1A1HPGD
SCHEMBL4333008 0.81 PTPN1 (0.66) KMT2AMAPTMEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 KMT2A 3988/4885MAPT 3619/4885MEN1 4874/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 KMT2A 3714/4885MAPT 3876/4885MEN1 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.